Developing New Outcome Measures, Functional Biomarkers & Clinical Research Regulatory Frameworks for Disease-Modifying Therapeutics Across Neurodevelopmental & Rare, Genetic CNS Disorders
With further clinical data emerging, drug development for rare CNS and neurodevelopmental disorders is advancing from hypotheticals to real-life clinical results, outcomes, and functional biomarkers; catapulting this critical field forwards to change patients’ lives.
The 2nd Rare CNS & Neurodevelopmental Drug Development Summit is the definitive industry-dedicated forum for large pharma, biotech, academia, and patient advocacy groups, paving the way towards symptomatic and successful disease modifying treatments.